CCEL Stock Overview
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Cryo-Cell International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.80 |
| 52 Week High | US$8.15 |
| 52 Week Low | US$3.67 |
| Beta | 0.55 |
| 1 Month Change | -2.99% |
| 3 Month Change | 41.05% |
| 1 Year Change | 37.08% |
| 3 Year Change | -10.24% |
| 5 Year Change | 10.01% |
| Change since IPO | -5.45% |
Recent News & Updates
Shareholder Returns
| CCEL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 5.8% | 0.6% | 1.0% |
| 1Y | 37.1% | 2.2% | 21.9% |
Return vs Industry: CCEL exceeded the US Healthcare industry which returned 3.4% over the past year.
Return vs Market: CCEL exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| CCEL volatility | |
|---|---|
| CCEL Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CCEL's share price has been volatile over the past 3 months.
Volatility Over Time: CCEL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 85 | David Portnoy | www.cryo-cell.com |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer’s disease, Parkinson’s diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells.
Cryo-Cell International, Inc. Fundamentals Summary
| CCEL fundamental statistics | |
|---|---|
| Market cap | US$63.21m |
| Earnings (TTM) | -US$9.73m |
| Revenue (TTM) | US$31.37m |
2.0x
P/S Ratio-6.5x
P/E RatioIs CCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCEL income statement (TTM) | |
|---|---|
| Revenue | US$31.37m |
| Cost of Revenue | US$12.27m |
| Gross Profit | US$19.10m |
| Other Expenses | US$28.83m |
| Earnings | -US$9.73m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 60.88% |
| Net Profit Margin | -31.02% |
| Debt/Equity Ratio | -101.9% |
How did CCEL perform over the long term?
See historical performance and comparison